本报告依据中国资产评估准则编制 陕西瑞盛生物科技有限公司拟股权收购事宜 涉及的常州武进金铂利口腔门诊部有限公司 股东全部权益 资产评估报告 中和谊评报字[2025]60041 北京中和谊资产评估有限公司 二○二五年十二月三十一日 | 报告编码: | 1111020029202500341 | | --- | --- | | 合同编号: | 20256038 | | 报告类型: | 非法定评估业务资产评估报告 | | 报告文号: | 中和谊评报字[2025]60041 | | 报告名称: | 陕西瑞盛生物科技有限公司拟股权收购事宜涉及的常州武进金铂 利口腔门诊部有限公司股东全部权益 | | 评估结论: | 27,700,000.00元 | | 评估报告日 : | 2025年12月31日 | | 评估机构名称: | 北京中和谊资产评估有限公司 | | 签名人员: | 王芳芳 (资产评估师) 正式会员 编号: 11230101 | | | 石俊杰 (资产评估师) 正式会员 编号:14230068 | | | 王芳芳、石俊杰已实名认可 | 声明 一、本资产评估报告依据财政部发布的资产评估基本准则和中国资产评估协会 发 ...

Group 1 - Aerospace Power's main business does not involve commercial aerospace, nor does it have any commercial aerospace-related assets for external investment [1] - Daye Co., Ltd.'s robotic tendon products are still in the exploratory testing phase and have not yet achieved mass production [1] Group 2 - Zhongyan Chemical plans to invest 83.9692 million yuan to expand its production capacity to 10,000 tons of metallic sodium and 15,500 tons of liquid nitrogen annually [1] - Huakang Clean has won the bid for the construction of the laboratory process project (Phase I, first opening area) in Dalian Yinggeshi Science City [1] Group 3 - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion yuan [1] - Green Island Wind's actual controller's concerted actors plan to reduce their holdings by no more than 1% of shares [1] Group 4 - Guangku Technology expects a year-on-year net profit increase of 152.00% to 172.00% in 2025 [1] - Zhaoli Technology is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [1]

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

Group 1: Mergers and Acquisitions - Haili Biological's subsidiary, Ruisheng Biological, plans to invest 61.2 million yuan to acquire 51% equity in seven dental chain companies located in Yangzhou and Changzhou, which is expected to increase the company's revenue by approximately 100 million yuan and net profit by over 7 million yuan [1] - Yanggu Huatai has decided to terminate the issuance of shares and cash payment to acquire 99.64% equity in Bomi Technology, opting to negotiate for partial equity acquisition in cash instead [2] - Yachuang Electronics intends to issue shares and pay cash totaling 317 million yuan to purchase 40% equity in Shenzhen Ouchuang Semiconductor and 45% equity in Shenzhen Yihai Nengda, constituting a major asset restructuring [3] Group 2: Earnings Forecasts - Guangku Technology anticipates a net profit attributable to shareholders of 169 million to 182 million yuan for 2025, representing a year-on-year growth of 152% to 172% [4] Group 3: Shareholding Changes - Jianzhijia's actual controller, Yunnan Xiangqun, plans to increase its stake in the company by up to 2% through a concentrated bidding process, with an investment amount of 50 million yuan sourced from its own funds and a loan of up to 45 million yuan from CITIC Bank [5] - Zhenzhong Investment, a significant shareholder of Lvdiaofeng, plans to reduce its stake by no more than 1% through a concentrated bidding process, equating to a maximum of 680,000 shares [6] - Two shareholders of Lingzhi Software plan to reduce their holdings by a combined total of up to 1.43%, with one shareholder reducing by up to 3.281 million shares (0.82% of total shares) and the other by up to 2.4492 million shares (0.61% of total shares) [7] Group 4: Tax Issues - Tianyue Advanced announced that it needs to pay a total of 82.9728 million yuan in corporate income tax and late fees, which will be recorded in the 2025 financial results, expected to reduce the company's net profit for that year [8] - China Pharmaceutical's wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical and Hainan Kangli Pharmaceutical, received tax notices requiring a total payment of approximately 65.2178 million yuan in taxes and late fees, which will also impact the company's net profit for 2025 [9][10] Group 5: Regulatory Issues - Platelite has received a notice from the China Securities Regulatory Commission regarding a case of suspected illegal information disclosure, leading to an official investigation [11] Group 6: Legal Matters - Baotailong announced that its subsidiary, Shuangyashan Longmei Tiantai Coal Chemical Co., is involved in a significant lawsuit that has entered the second instance, with a ruling requiring it to pay 316 million yuan in contract price and interest, while also receiving compensation and a return of a quality guarantee deposit [12]

Group 1 - The company, Haili Biological, announced that its 18th meeting of the fifth board of directors was held via communication on December 31, 2025 [1] - The meeting reviewed the proposal regarding the acquisition of equity in seven dental chain companies located in Yangzhou and Changzhou [1]

证券代码：603718 证券简称：海利生物 公告编号：2025－064 上海海利生物技术股份有限公司 第五届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海海利生物技术股份有限公司（以下简称"公司"）第五届董事会第十八次 会议通知于 2025 年 12 月 25 日以电子邮件和电话方式送达全体董事，于 2025 年 12 月 31 日下午以通讯方式召开。本次董事会会议应参加董事 7 人，实际参加董 事 7 名。本次会议符合《公司法》、《公司章程》和《董事会议事规则》的有关规 定，会议的召集、召开合法有效。 二、董事会会议审议情况 具体情况详见同日刊登于上海证券交易所网站（www.sse.com.cn）和公司指 定信息披露报刊《证券时报》、《证券日报》的《上海海利生物技术股份有限公司 经审议，本次董事会以通讯表决方式通过如下议案： 1、 审议通过了《关于控股子公司收购扬州、常州七家口腔连锁公司股权的议 案》 同意控股子公司陕西瑞盛生物科技有限公司（以下简称"瑞盛生物" ...

证券代码：603718 证券简称：海利生物 公告编号：2025－063 希格玛作为公司 2025 年度审计机构，原委派张建军先生、施煜女士作为签字 注册会计师为公司提供 2025 年度审计服务，因施煜女士工作调整，现委派陈飞先 生接替施煜女士作为签字注册会计师。变更后的签字注册会计师为：张建军先生、 陈飞先生。 二、本次新任签字注册会计师的基本情况 签字注册会计师：陈飞先生，现任希格玛会计师事务所（特殊普通合伙）项目 经理，2018 年 3 月开始从事审计专业服务工作，2020 年 9 月取得中国注册会计师 执业资格，2021 年 1 月开始在希格玛会计师事务所（特殊普通合伙）从事审计专业 服务工作，在公司年报审计、企业改制、专项审计、企业并购重组等方面具有丰富 的执业经验。拟从 2025 年起为公司提供审计服务，具备相应专业胜任能力。 签字注册会计师陈飞先生不存在违反《中国注册会计师职业道德守则》有关独 立性要求的情形，近三年内未曾因执业行为受到刑事处罚、行政处罚、监督管理措 施和自律监管措施、纪律处分。 上海海利生物技术股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在 ...

业绩承诺实现受市场、政策等多种因素的影响，如果在利润承诺期间出现影响 生产经营的不利因素，存在实际实现的净利润不能达到承诺净利润的风险，进而可 能导致商誉产生减值的风险，从而可能出现影响公司损益的风险。 证券代码：603718 证券简称：海利生物 公告编号：2025－065 上海海利生物技术股份有限公司 关于控股子公司收购扬州、常州七家口腔连锁公司股权 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 因本次交易尚未完成，相关资产的交割、过户等事项是否能最终顺利完成存在 不确定性，后续整合工作是否顺利完成存在不确定性风险。同时本次交易是公司通 投资金额：上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞 盛生物科技有限公司（以下简称"瑞盛生物"）拟以自有资金出资人民币 6,120 万元， 收购扬州、常州等七家口腔连锁公司（以下简称"标的公司"）各 51%的股权。 根据标的公司目前的盈利情况和业绩承诺（2026 年至 2028 年，需实现的经审计的净 利润分别为 1,400 万元、1,5 ...

每经AI快讯，海利生物12月31日晚间发布公告称，公司控股子公司瑞盛生物拟以自有资金出资人民币 6120万元，收购扬州、常州等七家口腔连锁公司各51%的股权。 （记者 曾健辉） 每经头条（nbdtoutiao）——最高返现60%！惠民保年末销售乱象调查：业务员"贴钱"冲考核，谁在"赔 本赚吆喝"？ 每日经济新闻 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

溧阳金铂利口腔门诊部有限公司 专 项 审 计 报 告 希会审字（2025）5425 号 目 录 一、审计报告 ………………………………（1-3） 二、财务报表 公司资产负债表…………………………（4-5） 三、财务报表附注 ……………………………（6-47） 四、证书复印件 （一）注册会计师资质证明 （二）会计师事务所营业执照 （三）会计师事务所执业证书 希格玛会计师事务所（特殊普通合伙） X i g e m a C p a s ( S p e c i a l G e n e r a l P a r t n e r s h i p ) 希会审字(2025）5425 号 专 项 审 计 报 告 陕西瑞盛生物科技有限公司： 一、审计意见 我们接受委托，审计了溧阳金铂利口腔门诊部有限公司（以下简称溧阳金铂 利）财务报表，包括 2025 年 11 月 30 日的资产负债表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照财务报表附注二所列的规定 编制，公允反映了溧阳金铂利 2025 年 11 月 30 日的财务状况。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告 ...